Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
07:00am, Monday, 14'th Apr 2025
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity an
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
09:58pm, Thursday, 20'th Mar 2025
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President and Chief Exec
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
07:00am, Friday, 14'th Mar 2025
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and ot
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Thursday, 27'th Feb 2025
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic h
Skye Bioscience to Present at TD Cowen Health Care Conference
07:00am, Thursday, 20'th Feb 2025
SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obe
Skye Bioscience Announces Participation in February Conferences
07:00am, Tuesday, 04'th Feb 2025
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and
MoneyShow's Best Investment Ideas For 2025: Part 8
09:20am, Monday, 03'rd Feb 2025
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
07:00am, Thursday, 19'th Dec 2024
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and
Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy
08:32am, Tuesday, 10'th Dec 2024
Skye Bioscience's Nimacimab shows promising Phase 1 safety data and is in Phase 2 trials, potentially revolutionizing obesity treatment with minimal neuropsychiatric side effects. Nimacimab's large-mo
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
07:00am, Thursday, 14'th Nov 2024
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic h
Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript
10:36pm, Thursday, 07'th Nov 2024
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Bernie Hertel - Head, Investor Relations Punit Dhillon - President and CEO Kaitly
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
04:01pm, Thursday, 07'th Nov 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pat
Skye Bioscience to Announce Third Quarter 2024 Results
07:00am, Friday, 01'st Nov 2024
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic h
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
07:00am, Monday, 21'st Oct 2024
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic h
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
08:46am, Wednesday, 09'th Oct 2024
Skye Bioscience NASDAQ: SKYE is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) a
